Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lymphoma

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017;23:4127–37. https://doi.org/10.1158/1078-0432.CCR-16-2818.

    Article  CAS  PubMed  Google Scholar 

  2. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–7.

    Article  CAS  Google Scholar 

  3. Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–31. https://doi.org/10.1016/S1470-2045(15)00559-8.

    Article  CAS  PubMed  Google Scholar 

  4. Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2018;180:224–35. https://doi.org/10.1111/bjh.15025.

    Article  CAS  PubMed  Google Scholar 

  5. Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912–9.

    Article  CAS  Google Scholar 

  6. Leonard JP, Jung S-H, Johnson J, Pitcher BN, Bartlett NL, Blum KA, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635–40.

    Article  CAS  Google Scholar 

  7. Martin P, Jung S-H, Pitcher B, Bartlett NL, Blum KA, Shea T, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol J Eur Soc Med Oncol. 2017;28:2806–12.

    Article  CAS  Google Scholar 

  8. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012. https://doi.org/10.1016/S1470-2045(12)70200-0.

    Article  Google Scholar 

  9. Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–44.

    Article  CAS  Google Scholar 

  10. Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011. https://doi.org/10.1016/j.clml.2011.02.001.

    Article  CAS  Google Scholar 

  11. Ivanov V, Coso D, Chetaille B, Esterni B, Olive D, Aurran-Schleinitz T, et al. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2014. https://doi.org/10.3109/10428194.2014.889822.

    Article  CAS  Google Scholar 

  12. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013. https://doi.org/10.1038/leu.2013.95.

    Article  CAS  Google Scholar 

  13. Zinzani PL, Pellegrini C, Argnani L, Broccoli A. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica. 2016;101:e385–6.

    Article  Google Scholar 

  14. Morschhauser F, Salles G, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, et al. An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood. 2018. https://doi.org/10.1182/blood-2018-05-853499.

    Article  CAS  Google Scholar 

  15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. J Clin Oncol. PMID: 10561185. https://doi.org/10.1200/JCO.1999.17.4.1244.

    Article  CAS  Google Scholar 

  16. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.

    Article  CAS  Google Scholar 

  17. Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–37. JCO.2017.73.340.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the patients and their families; the Lymphoma Academic Research Organization team for the management of the study, in particular Elise Gaire and Clémentine Joubert; the reviewers at the Lymphoma Study Association (LYSA) notably Luc Xerri, Peggy Dartigues, Bettina Fabiani, Danielle Canioni, Catherine Chassagne-Clement, Camille Laurent, Véronique Meignin; the Independent Data Monitoring Committee (André Bosly, Catherine Sebban, and Natacha Heutte); and all the investigators. Funding support and drug supply were provided by F. Hoffmann La Roche Ltd and Celgene Corporation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Franck Morschhauser.

Ethics declarations

Conflict of interest

RH: Honoraria: Bristol-Myers Squibb, Novartis, Janssen, Celgene, Consultant: Bristol-Myers Squibb; GC: Honoraria: Sanofi, Gilead, Janssen, Roche, Celgene, Consultant: Roche and Celgene; GS: Honoraria: Novartis Pharmaceuticals Corporation, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Kite, Merck, Servier, Morphosys, Roche, Grants: Roche; KB: Honoraria: Takeda, Roche, Gilead, Advisory Board: Takeda, Roche; MM: Travel grants: Gilead, Roche, Abbvie, Advisory board: Abbvie, Takeda; PF: Honoraria: Gilead, Roche, Abbvie, Janssen, Consultant: Janssen, Gilead; SLG: Honoraria: Roche, Janssen, Celgene, Servier, Gilead, Advisory board: Roche, Janssen, Celgene, Research funding: Roche, Janssen, Celgene; HT: Honoraria: Celgene, Roche, Karyopharm, Astra-Zeneca, Bristol-Myers Squibb, Grants: Celgene; ROC: Honoraria: Celgene, Abbvie, Janssen, Consultant: Roche, Takeda, Merck, BMS, Research funding: Roche, Gilead; MA: Advisory Board: Celgene, Grants: Celgene, Roche; CB: Advisory board: Roche and Janssen; CA: Advisory Board: Roche, Celgene, Takeda, Janssen, Amgen, Kite/Gilead; ENV: Consultant: Janssen, Keocyt et Sanofi; FM: Advisory Board: Roche, Celgene, Janssen, BMS, Gilead, Consultant: Epizyme, Gilead. All the remaining authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Houot, R., Cartron, G., Bijou, F. et al. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. Leukemia 33, 776–780 (2019). https://doi.org/10.1038/s41375-018-0282-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0282-y

This article is cited by

Search

Quick links